Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy (NYRVANA)

2. september 2026 opdateret af: SparingVision

A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy

This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is an open-label, non-randomized, multi-center, dose-escalation and dose-expansion, first-in-human, Phase I/IIa study. Participants will be followed for a total of five years after receiving a single unilateral intravitreal injection of SPVN20 in their study eye, and will be monitored by an independent Data Safety Monitoring Committee. Eligible patients will be assigned by sequential enrollment to one of the following three cohorts:

Cohort 1: low dose of SPVN20 will be evaluated in a total of 9 participants. Cohort 2: medium dose of SPVN20 will be evaluated in a total of 9 participants. Cohort 3: high dose of SPVN20 will be evaluated in a total of 9 participants.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

27

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Belgien
      • Ghent, Belgien
        • Rekruttering
        • Ghent University Hospital
        • Kontakt:
          • Ophthalmic Clinical Trials Unit
          • Telefonnummer: 00 32 9 332 23
          • E-mail: OCTU@uzgent.be
        • Ledende efterforsker:
          • Prof. Dr. Bart Leroy
  • Frankrig
      • Paris, Frankrig, 75012
        • Rekruttering
        • CHNO XV-XX Paris - CIC 1423
        • Kontakt:
        • Ledende efterforsker:
          • Dr Amine Benadji
  • Irland
      • Dublin, Irland
        • Rekruttering
        • Royal Victoria Eye and Ear Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Dr Emma Duignan

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years old at enrollment.
  2. Participant with a genetically confirmed clinical diagnosis of advanced RCD in both eyes due to non-syndromic RCD.
  3. Participants enrolled in the Dose-Escalation cohorts must have a BCVA meeting the study eye criteria.
  4. Documented preservation of foveal cone cell bodies in the study eye (as shown on SD-OCT imaging).
  5. Participant with a history of formed vision.
  6. Participant willing and able to provide informed consent.

Exclusion Criteria:

  1. Participant participating in another clinical trial and receiving an investigational medicinal product (IMP) within either 5 half-lives of that IMP, or 90 days prior to the injection of SPVN20.
  2. Participant with cortical visual impairment.
  3. Participant with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision.
  4. Participant with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen.
  5. Participant who has received immunosuppressive therapies or any other therapy known to impact the immune system during the last month prior to SPVN20 administration.
  6. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
  7. Participant known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
  8. Active alcohol or substance abuse.
  9. Participant positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
  10. Participant with active Hepatitis B or Hepatitis C.
  11. Female participant currently pregnant or breastfeeding or intending to become pregnant.
  12. Participant with clinically active ocular infection of herpetic diseases.
  13. Participant with active coronavirus disease (COVID-19) infection.
  14. Participant who received any vaccination/immunization within 28 days prior to screening and/or during screening.
  15. Participant who previously received any gene therapy product, stem cell therapy, cell-based therapy for ocular or non-ocular disease.
  16. Participant with a retinal implant at enrollment.
  17. Participant with pre-existing eye conditions that would interfere with the interpretation of study endpoints, or increase the risk of surgical complications.
  18. Participant with significant media opacity impacting evaluation of the retina or vitreous.
  19. Participant who had intraocular surgery within 90 days of study treatment administration.
  20. Participant with history of corticosteroid-induced raised IOP of >25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy.
  21. Participant with history of unresolved rhegmatogenous retinal detachment in the fovea.
  22. Participant with history of unresolved ocular hypotony.
  23. Participant unwilling or unable (based on the Investigator's judgment) to comply with the study protocol.
  24. Participant with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the Investigator, would make them unsuitable for the study.
  25. Participant currently taking restricted classes of medications listed in protocol
  26. Participant with ongoing cardiac or neurological disorders not managed by a restricted medication can be excluded based on the Investigator's judgement.
  27. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential who do not agree to use a highly effective contraceptive method.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: SPVN20 (low dose). Single intravitreal injection of a low dose of SPVN20 on Day 0
SPVN20
Biologisk: SPVN20 (low dose)
SPVN20
Eksperimentel: SPVN20 (medium dose). Single intravitreal injection of a medium dose of SPVN20 on Day 0
SPVN20
Biologisk: SPVN20 (medium dose)
SPVN20
Eksperimentel: SPVN20 (high dose). Single intravitreal injection of a high dose of SPVN20 on Day 0
SPVN20
Biologisk: SPVN20 (high dose)
SPVN20

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and Tolerability
Tidsramme: 6 months
Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
6 months
Ocular safety
Tidsramme: 6 months
General ocular assessments including complete ophthalmic examination of extraocular and intraocular structures
6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Best Corrected Visual Acuity (BCVA)
Tidsramme: 6 months
Change in BCVA from Baseline to Month 6 after dosing with SPVN20.
6 months
Full-field stimulus threshold (FST) test
Tidsramme: 6 months
Change in FST from Baseline to Month 6 after dosing with SPVN20
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

SparingVision

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. oktober 2025

Primær færdiggørelse (Anslået)

1. marts 2032

Studieafslutning (Anslået)

1. marts 2032

Datoer for studieregistrering

Først indsendt

10. august 2026

Først indsendt, der opfyldte QC-kriterier

2. september 2026

Først opslået (Faktiske)

8. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • SPVN20-CLIN-01
  • 2025 (U.S. NIH-bevilling/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-520665-47-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner